Takeda signs $882m rare disease alliance with Oxford biotech EvoxEvox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, Share XTakeda signs $882m rare disease alliance with Oxford biotech Evoxhttps://pharmaphorum.com/news/takeda-signs-882m-rare-disease-alliance-with-oxford-biotech-evox/
Takeda’s Ninlaro falls short in first line multiple myelomaTakeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid Share XTakeda’s Ninlaro falls short in first line multiple myelomahttps://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/
Takeda and Arcturus join hunt for coronavirus therapiesThe Japanese drugs giant Takeda and the US biotech Arcturus Therapeutics have joined the hunt for therapies for Share XTakeda and Arcturus join hunt for coronavirus therapieshttps://pharmaphorum.com/news/takeda-and-arcturus-join-hunt-for-coronavirus-therapies/
Boehringer bags CHMP backing for Ofev in rare lung diseaseBoehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the Share XBoehringer bags CHMP backing for Ofev in rare lung diseasehttps://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/
Takeda buys US biotech PvP Biologics for $330 millionTakeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for Share XTakeda buys US biotech PvP Biologics for $330 millionhttps://pharmaphorum.com/news/takeda-buys-us-biotech-pvp-biologics-for-330-million/
Chiesi starts rare diseases division, ahead of potential Fabry disease filingItalian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch Share XChiesi starts rare diseases division, ahead of potential Fabry disease filinghttps://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
UK leaders: Takeda’s Jon NealIn the first of a new series where we talk to GMs of UK pharma divisions, managing director Share XUK leaders: Takeda’s Jon Nealhttps://pharmaphorum.com/views-analysis-market-access/uk-leaders-takeda-jon-neal/
Takeda invests in patient-centric data firm SeqsterUS startup Seqster, which it claims to “put the person at the centre of healthcare”, has just attracted Share XTakeda invests in patient-centric data firm Seqsterhttps://pharmaphorum.com/news/takeda-invests-in-patient-centric-data-firm-seqster/
